Araştırma Makalesi

Impact of genistein on androgen-independent PC3 prostate cancer cells

Cilt: 50 Sayı: 1 31 Mart 2025
PDF İndir
EN TR

Impact of genistein on androgen-independent PC3 prostate cancer cells

Abstract

Purpose: This study evaluates genistein’s effects on cell survival, migration, apoptosis, reactive oxygen species (ROS) generation, and Manganese Superoxide Dismutase (MnSOD) expression in androgen-independent PC3 prostate cancer cells, providing insight into its potential as an adjuvant therapy for castration-resistant prostate cancer (CRPC). Materials and Methods: Cells were treated with vehicle only and 0.5, 2.5, 5, 10, and 50 µM genistein concentrations for 24 and 48 hours. Cell proliferation assay, wound healing assay, ROS measurement, apoptosis detection, and MnSOD protein expression analysis were performed. Results: The findings indicate a biphasic effect of genistein on PC3 cell survival. Lower to physiologically relevant concentrations (0.5–10 µM) exhibit a modest stimulatory effect, whereas a higher, pharmacologically achievable concentration (50 µM) leads to a time-dependent decline in survival and a significant restriction on migration. In vehicle-treated cells, 77% remained viable, with low early (3.65%) and late apoptosis (16.35%). Lower genistein concentrations (0.5–10 µM) caused a slight increase in apoptosis and a modest decline in viability. However, at 50 µM, only 18.7% of cells remained viable, while 74.25% underwent late apoptosis or cell death. Conclusion: These findings demonstrate that genistein, particularly at higher concentrations, inhibits androgen-independent PC3 cell growth through apoptosis induction, MnSOD regulation, and elevated oxidative stress.

Keywords

androgen-independent prostate cancer cells , genistein , cell migration , ROS production , cell survival , apoptosis.

Kaynakça

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2021;71:209–249.
  2. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4:365-80.
  3. Joshi H, Gupta DS, Abjani NK, Kaur G, Mohan CD, Kaur J et al. Genistein: a promising modulator of apoptosis and survival signaling in cancer. Naunyn Schmiedebergs Arch Pharmacol. 2023;396:2893-2910.
  4. Sawada N, Iwasaki M, Yamaji T, Shimazu T, Inoue M, Tsugane S. Japan Public Health Center-based Prospective Study Group. Soy and isoflavone consumption and subsequent risk of prostate cancer mortality: the Japan Public Health Center-based Prospective Study. Int J Epidemiol. 2020;49:1553-1561.
  5. Sharifi-Rad J, Quispe C, Imran M, Rauf A, Nadeem M, Gondal TA et al. Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits. Oxid Med Cell Longev. 2021;2021:3268136.
  6. Liu Y, Kyle E, Lieberman R, Crowell J, Kellof G, Bergan RC. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation. Clin Exp Metastasis. 2000;18:203-12.
  7. Hörmann V, Kumi-Diaka J, Durity M, Rathinavelu A. Anticancer activities of genistein-topotecan combination in prostate cancer cells. J Cell Mol Med. 2012;16:2631-6.
  8. Fu Z, Cao X, Liu L, Cao X, Cui Y, Li X et al. Genistein inhibits lung cancer cell stem-like characteristics by modulating MnSOD and FoxM1 expression. Oncol Lett. 2020;20:2506-2515.
  9. Rasheed S, Rehman K, Shahid M, Suhail S, Akash MSH. Therapeutic potentials of genistein: New insights and perspectives. J Food Biochem. 2022;46:e14228.
  10. Jordaens L, Arias-Alvarez M, Pintelon I, Thys S, Valckx S, Dezhkam Y et al. Elevated non-esterified fatty acid concentrations hamper bovine oviductal epithelial cell physiology in three different in vitro culture systems. Theriogenology. 2015;84:899-910.

Kaynak Göster

MLA
Özten Kandaş, Nur, vd. “Impact of genistein on androgen-independent PC3 prostate cancer cells”. Cukurova Medical Journal, c. 50, sy 1, Mart 2025, ss. 231-40, doi:10.17826/cumj.1633575.